15. Ulusal Meme Hastalıkları Kongresi, Antalya, Turkey, 17 - 20 October 2019, pp.28
Objective: The benefit of neoadjuvant chemotherapy (NACT) and postoperative radiotherapy (RT) on local - regional survival and overall survival remains unclear. The aim of this study was to investigate the outcomes of patients with stage II - IIIA breast cancer who underwent NACT
and postoperative RT.
Material and methods: Data of 85 breast cancer patients admitted to our clinic between 2014 and 2017 after NACT and surgery were analyzed
and 66 patients with stage II-IIIA were included in the study. General characteristics of the patients are listed in Table 1. Statistical analysis was
performed using SPSS software 23.0 (IBM Corporation, Armonk, NY, USA). For disease-free survival (DFS) and overall survival (OS), the
biopsy date was determined as the first diagnosis date and Kaplan-Meier method was used for analysis.
Results: The median follow-up period was 32 months. All patients received NACT and 33% underwent breast conserving surgery. Nine patients
(13.6%) underwent nipple sparing mastectomy and reconstruction with prosthesis, while only one patient (3%) underwent skin sparing mastectomy. Pathologic complete response (pCR) was observed in 24.2% of the patients. When the complete response rates were evaluated according
to the molecular subgroups of the patients, pCR rates were significantly higher in patients with her-2 positivity. Patients received adjuvant RT
after surgery. For 3-year DFS is 89% and OS is 92%.
Conclusion: Early results of stage II-IIA breast cancer patients who underwent neoadjuvant chemotherapy were obtained. RT has been
applied to all patients and with the conclusion of randomized trials, it is expected that the groups that will benefit from RT will be better